Mahamaya Lifesciences IPO Details
The key details of Mahamaya Lifesciences’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹70.44 Cr |
| Price Range | ₹108 - ₹114 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | BSE |
| Minimum Quantity | 2,400 |
| Investment (cut-off price) | ₹2,73,600 |
| Pre IPO Promotor Holding | 77.27% |
| Post IPO Promotor Holding | 56.35% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Mahamaya Lifesciences IPO Timelines
The IPO process for Mahamaya Lifesciences includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
11/11/2025
Start Date13/11/2025
End Date17/11/2025
Refund Initiation17/11/2025
Credit of Shares to Demat Ac18/11/2025
Listing DateMahamaya Lifesciences IPO Lot Size
The Mahamaya Lifesciences IPO has a fixed lot size of 1,200 shares, at an upper price band of ₹114 per share. For retail investors, the minimum and maximum application is 2,400 shares (2 lots) amounting to ₹2,73,600. For Small HNI (S-HNI) investors, the minimum application is 3,600 shares (3 lots) worth ₹4,10,400, while the maximum is 8,400 shares (7 lots) amounting to ₹9,57,600. Big HNI (B-HNI) investors need to apply for at least 9,600 shares (8 lots), totaling ₹10,94,400.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2400 | ₹2,73,600 |
| Retail Maximum | 2 | 2400 | ₹2,73,600 |
| S-HNI Minimum | 3 | 3600 | ₹4,10,400 |
| S-HNI Maximum | 7 | 8400 | ₹9,57,600 |
| B-HNI Minimum | 8 | 9600 | ₹10,94,400 |
Mahamaya Lifesciences IPO Subscription Status
The subscription status for Mahamaya Lifesciences IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 1.19x | 3.63x | 1.02x | -- | 1.63x |
IPO Performance on Listing Day
On its listing day (November 18, 2025), Mahamaya Lifesciences IPO delivered a moderate debut on the exchanges. The stock opened at ₹116, reflecting a 1.75% premium over the issue price of ₹114. It moved up to an intraday high of ₹121.80, before facing selling pressure and slipping to a low of ₹115 which was also its closing price. Despite the pullback from the highs, the stock still ended the day with a 0.87% gain over the issue price, indicating cautious but positive investor sentiment in the lifesciences sector.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹116.00 | ₹115.00 | ₹121.80 | ₹115.00 |
Mahamaya Lifesciences IPO Company Financials
Mahamaya Lifesciences reports robust performance in FY2025 with Total Income of ₹267.17 crores, managing expenses at ₹249.81 crores, and achieving a strong PAT (Profit After Tax) of ₹12.94 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹137.40 | ₹132.30 | ₹3.75 |
| FY 2024 | ₹162.83 | ₹155.71 | ₹5.22 |
| FY 2025 | ₹267.17 | ₹249.81 | ₹12.94 |
| FY 2026 (3 M) | ₹84.04 | ₹78.35 | ₹4.10 |
About Company
Incorporated in 2002, Mahamaya Lifesciences Limited is a leading manufacturer, registrar, and exporter of high-quality crop protection products and bioproducts aimed at enhancing crop and soil health for improved agricultural productivity. The company specializes in producing pesticide formulations and supplying bulk products to both Indian agrochemical companies and multinational corporations (MNCs). By importing scientifically developed molecules, registering them with the Central Insecticides Board, and developing value-added formulations, Mahamaya Lifesciences plays a crucial role in supporting domestic and global agrochemical markets.
The company has expanded its presence internationally, investing in global product registrations and actively operating in markets such as the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey. Its diverse product portfolio includes bulk formulations like Acetamiprid SP and Emamectin Benzoate SG; technical products such as Imidacloprid and Atrazine; and branded formulations like MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, and UCHIT EW 370. In addition, the company exports popular formulations including Wiper (Sulphur 80% WDG) and Lancha (Pendimethalin 50% EC), underscoring its commitment to quality, innovation, and sustainable growth in the agrochemical industry.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2002 | Chemicals | Click Here |
Know Before Investing
Mahamaya Lifesciences IPO Strengths
- The company has grown its total income steadily from ₹90.16 crore in FY22 to ₹267.17 crore in FY25, showing strong scalability.
- Mahamaya focuses on bio-based crop care products including bio-stimulants, bio-fertilizers, and eco-friendly insecticides promoting sustainable agriculture.
- Their have a well-established dealer network across six states and exports to countries like Dominican Republic, Turkey, Egypt, and UAE.
- Continuous efforts in product registrations and new bio-molecule development help expand the product pipeline and market opportunities.
- The founding team has deep experience in agritech and chemical formulations, steering growth and strategy.
- The Dahej, Gujarat plant is well-equipped for technical formulation production, meeting domestic and export standards.
Mahamaya Lifesciences IPO Risks
- Fluctuations in prices and supply of key bio-based ingredients could impact margins and production efficiency.
- Current revenue relies heavily on select states and dealers, which poses concentration risk.
- Changes in agricultural, environmental, or export regulations could result in delayed product approvals or increased compliance costs.
- New products must undergo registration processes which carry uncertainty and can delay market entry.
- Growing inventory and receivables necessary for expansion could strain liquidity during certain business cycles.
- Crop production and demand for bio-inputs depend on weather patterns and agricultural policies.
- Moderate company size compared to large agritech firms may limit bargaining power and economies of scale.
Swot Analysis for Mahamaya Lifesciences IPO
Strengths
Early Mover Advantage, Strong Distribution Network, International Export Reach
Weaknesses
Raw Material Price Sensitivity, Limited Brand Recognition, Geographic Concentration
Opportunities
Growing Crop Care Market, Expanding Dealer Network, Global Market Expansion
Threats
Intense Industry Competition, Raw Material Supply Risks, Agricultural Sector Cyclicality
Company Details
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor, Plot No: 79 – 80, DLF Prime Tower, Block, Okhla, Phase – 1, Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
IPO Registar Details
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: mahamaya.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/
FAQs
The key objectives of Mahamaya Lifesciences SME IPO are:
- Purchase of Equipment for existing Formulation plant
- Funding capital expenditure towards setting up of a new technical manufacturing plant
- Construction of Warehouse Building and Purchase of Machinery
- Funding working capital requirement of Company
- General Corporate purposes
Oneview Corporate Advisors Pvt. Ltd. is the book-running lead managers for the Mahamaya Lifesciences IPO.
Mahamaya Lifesciences IPO shows strong growth potential supported by revenue rising from ₹90.16 crore in FY22 to ₹162.83 crore in FY24 and profit reaching ₹12.94 crore in FY25. Its expansion into eco-friendly biological crop care products and global market presence positions it well for sustainable future growth.
The issue price for the Mahamaya Lifesciences IPO is set between ₹108 to ₹114 per share.
To invest in two lot of Mahamaya Lifesciences IPO, you need ₹2,59,200 at the lower price band (₹108 per share) or ₹2,73,600 at the upper price band (₹114 per share) for a lot size of 2400 shares.
Mahamaya Lifesciences IPO shares are scheduled to be listed on the Bombay Stock Exchange (BSE) on November 18, 2025.
Refund/unblocking of funds for Mahamaya Lifesciences IPO will begin on November 17, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Mahamaya Lifesciences IPO shares on listing day (November 18, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.